Glaukos: Specialist in Ophthalmology Grows by 50% Thanks to iDose TR Demand
Reading Time: 3 minutes
Glaukos focuses on ophthalmology with tiny implants and therapies. The second quarter impresses with record revenue, showing a growth of 50%. iDose TR and the new Epioxa become important growth drivers. Citi analysts are optimistic about the quarterly figures of medical technology companies and raised the price target from $188 to $225 (Buy) on August 13. Glaukos (GKOS) is one of the leading medical technology companies in the field of ophthalmology, developing minimally invasive therapies for glaucoma, corneal diseases, and retinal...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
